On the other hand, the dual co-agonist LY3298176 (tirzepatide) biased towards GIPR agonism obtained promising results as antidiabetic treatments in T2DM clinical trials as it showed improvements in glycemic and body weight control although is also showed an increased pulse rate [77,78,96]. The gene discussed is GIPR; the disease is type 2 diabetes mellitus.